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Introduction
.\lmost 1\\0 decades after the introduction ofmodern
methods of imlllunosuppression. transplantation of
organs and tissues has became an established specialty.
rill:' theories in regard to the transfusion support needed
by these patients have. also matured a lot. Tn early
eighties patients had been heavily transfused before
1IlH.krgoing liver or kidney transplantation. and thus were
c\poscd to attendant risks and complications of
alloimmuni/ation to red cells and Human Leucocyte
Antigens (lILA). Kiclnc)' transplant candidates received
elective i111ll1UIlOlllodulatof) red cell transfusions to
imprO\ e gran suni\'al. The advent ofcyclosporin made
this a(I\'antage marginal at best. Few programmes now
usc elccti\c prc-transplant transfusions to improve gran
sUI'\,j\al Nowadays most of the patients with chronic
renal failure are gi\'cn erythropoietin to avoid transfusion.
Patient wllh end staged liver diseases have been treated
b) drug octreotidc. variceal banding. sclerotherapy,
transjugular intrahepatic portosystamic shunt
placements to relievc Lhc effects ofportal hypertension
in order to ha\·c Jess gastrointestinal bleeding and to
a\'oid transfusion (I). This review will summarize the
current concepts regarding the role of transfusion
ser\ices in potential organ or tissue transplant recipients.
Ilospital Transfusion Services playa great role in
clinical transplantation programme. Close
communication \\ith transplant surgeons and other
professional involved in the program is cssential.
Morbidity. monaiit) and graft suni\'all'an be measured
against the transfusion of blood components pnor to.
during. and after transplantati()IL
Information of special importance to hlood
transfusion services could include
1. lIislory of previous pregnanc). Iransfusion or
transplantation.
2 Laboratory tests e.g.. ABO Grouping. Rh l~ ping.
direct antiglobulin test (AGT). red cel·] antibod) sl.:n:cning
and test far cytomcgala virus (CMV).
3. II LA typing and II LA ,1I1tibadics studies an: routine
for organ and bone marro\\ r~cipiellts. Additional t~sts
might include subgrouping or those paticllIs \\ ho aJ'~ ofA
or AS blood group. and an alllibody detcction tests in thl:
recipients using enzyme treated red cells. PhenOl) ping of
red cells of the donor and patient ma) b~ performed in
order to follow the cngraftmenl oftransfuscd bonl,.' 111:1rro\\.
ABO Grouping:- ABO Antigcns constitute \·cr~ strong
histocompatibility antigens and thus thc) are of major
importance in transplantation. Sincc thesc antigens are
c>..pressed on vascular cndothelium. ABO mismatch tan
cause rapid graft rejection due to endothelial dallli.lg~ b)
ABO alloanlibody and subsequent \\ ide spread
thrombosis with the graft. Thcrcfon:. AnO matching is
veryimportant in the transplantation oflhe organs that
are celluiarand ha\'c good blood suppl~ i.e." idll~). heart.
liver and pancreas.
Renal Transplant
Once the policy ofavoidancc oftransfusion ha:, hl:cn
replaced by the programmcs ofintcntionaltri.lllsfusions.
From the Departmenfsof""Transfusion Medicinc,""""Gencr'al Surgery,""""*ENT & """""""'Pacdiatrics SKIMS SOllnl and SKIMS
~]edic.lICollcgc Hospital, Bcmina,Srinagar(J&K) India.
Corrcspondcnce to : Dr. Rafiq A Calcutti, DepartmentoITransfusion Medicine. SKIMSMedical College. Semina.Slinagar(J&K) India.
Vol. ~ No...I-. October-December 2002 163______________~.~JK SCIE CE
rhis in turn. has been associated with significant
impro\'emcnt in the outcome of 1110st of the transplants
but not in all. In 1970's intentional pretransplant blood
transfusion protocol started and data accumulated all
over the world supported the thesis of Opezl et al -
prctransplanl blood transfusion enhanced renal allograft
slIni\al C~). l:.vcn the a~vent ofimlllunosuppressive drug
c)closporine has not altered the recommendation for
pr~transplant transfusion. Although there seems to be
some lessening of the benefits of transfusion in
c)"closporin treated patients.
The way in which transfusion enhances transplant
sUl'vi\ al is unknown, but sevcralmcchanisl11s have been
postulated e.g.
\. Prelransplanl transfusion may result in early
immunization ofsome persons to selected HLA antigens.
Lhcrcb) enabling the pretransplantation crossmatch to
detcct those cases where rejection of donor organ would
be most likely to occur. Preformed HLA antibody as
manifested by incompatible crossmatch is a major
conlrClindication to transplantation, and about 30% ofcases
who receive pretranplant transfusions become highly
immunized to liLA. This complication of prelransplant
transfusion may, infect be beneficial by preventing an
unsuccessful transplant.
2 The beneficial effect oftransfusion is related to the
immunosuppression induced by transfusion. Perhaps
through the enhancement ofsuppressor T cell activity, other
possibilities include induction ofinunune tolerance by some
unknown mechanism, stimulation ofanti idiotypic antibody
production and, then while they are actively proliferating,
and destroy them by immunosuppressive drugs.
It is 110t clear which component of the transfused
blood is responsible for more beneficial effect. Althougb
leukocyte poor red cells. and frozen deglycerolized red.
cells are assumed to have low incidence of HLA
iml11unization (3-4). Also the incidence of
alloillllllunization seems to be low when stored units,
rather fresh units of blood are used for transfusion (5).
CMV infection, a major cause of morbidity and
mortality in patients who have had renal transplant seems
to be related to the presence of CMV in donor kidney.
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There is no evidence to incriminate blood or blood
products as the source and no need to pro\ ide CMY
negative components for kidney transplant recipients.
Survival of kidney gran li'om living related donors is
enhanced by the pregraft conditioning of the recipient
with several transfusions. their volume. and which
portion of blood is beneficial are not established. but
one protocol uses three aliquots from a single donation.
given at 2-3 weeks intervals before transplantation (6).
This is used by draining one unit of blood from the
donor, preparing red blood cells from i1. and separating
the red eell unit into three aliquots us;ng a doublc or
triple bag. Each ofthem can be used for up to 42 days.
Although numcrous other protocols exist. until rccently
most transfusion services transfuse at least 5 UllilS of
blood to all new dialysis patients awaiting renal transplant
(7). These were usually given in the form ofwhitc blood
cells (WBC). however Red blood cells (RBC).
deglycerilized RBC's and buffy coats are effecti\e
alternatives to whole blood. Preoperative blood
transfusion at the time ofsurgery is usually 1101 effective.
It should be given at least 3 to 6 months prior to
transplant (8).
At times it may be advisable to give donor specific
transfusions from Rhesus D positive donor to Rhesus
o negative recipient. Separating red cells from ButT)
coat by using hydroxyethyl starch (HES) can do this.
However. some red cells still remain present in the Buffy
coal and are quite enough to immunize the recipient. A
full dose of(i.e., 350-mg) ofRh immune globulin (RhIG)
should be givel1 to the recipient for the entire course of
transfusion (9). Wben 0 group individuals' kidney is
transplanted into a 11011-0 group individual. it is possible
that "Passenger Lymphocytes" present in the kidney at
the time of transplant can become engrafted into tbe
immunocompromized recipient. If these lymphocytes
are programmed to produce anti A or anti B, then at
times they can produce ABO antibodies directed against
the recipients erythrocytes, these complications are
marked by a positive direct AG:r tcst and hemolytic
anemia (10). Where as when two Rhesus D positive
patients wer.e transplanted from previously immunized
Rhesus 0 negative donors, have shown temporary
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Rhcscs D itlllllUI1ization and hemelytic anemia (1 I). tranaplant patients usually have pre-existinganalOm ic prob-
Liver Transplant lems such as severe portal hypertension and abdominal
I jYcr transplant programmes demand the adhesiol1s. orthey develop hemodynamic instability. shock,
maximum support in terms of preparedness, supply exacerbation ofcoagulopathy (15).
and responsiveness. Institutions that begin the liver Cardiac Transplant
transplant programme must make a major Transfusion support of cardiac transplant is similar
commitment to this support. Co-operations between to that ofopen-heart surgery in which cardiopulmonary
the hospital administration, staff of the operating bypass is employed.
rOOI11, inlcl1sive care unit, respiratory therapy, Postoperative needs vary according to individual's
radiology. gastrocntrology, anesthesiology, clinical circumstances. but for the typical organ trans-
coagulation laboratory and transfusion services. Most plant recipient postoperative transfusion are not needed.
orthe liver Iransplant centers currenlly use a mcdium Pancreatic Transplant
of 12 units ofallogcnic red cells. 15-20 units of fresh Pancreatic transfusions do not requirc any tnlllsfu-
frozen plasma (FFP), 2 doses of platelets (1 dose of sian support. However either a type and screening of
platelet 6 units of" platclet conccntrates (PC) or I complete crossmatching of few RBC units should be
unit ofaphcresis platelcl concentrate (APC)), 8 unils established as a routine.
of cryoppt. Children may require half of lhese Bone MalTOW Transplant
amOLlnts (12.13) Patients undergoing bone marro\\ transplant orten
The medium ranges ofblood and components used require prolonged blood component support. This is
in li\'Cr transplant are shown in table (I &2). bccause thcre is complete ablation oftheir 0\\'11 marrow
Red cell salvagcshould aggressively be employed, trans- before transplantalion and a rclativcly long period beforc
fusion services and hcmostasis laboratory should be in- the engrafted marrow begins Lo function. In addition
\"ohcd in monitoring hcmostasis, including they are pronc to devclop graft verses host disease and
thromboelectrography to detect fibrinolysis (14). Liver CMV infection. and all the blood products must be
Table 1. Examples ofroutine preoperative surgical blood ordersfor organ transplantation*
Number ofunits
Components Living donor Kidney Heart Pancreas bone marrow Liver
Nephropathy
ROC 0#-2 0#-2 5-10 0#-4 0 20
PC 0 0 8 0 0 20
FFP 0 0 2 0 0 20
* Preopcratin~ needs vary according to individual clinical circumstances, but for the typical organ reCipient. pOSlOpenltl\'c
blood components are not except bone marrow and liver transplant.
# type and screen or no blood orders.
T:tblc 2. Examples ofIInits ofblood components transfused in adult Iiyer transplallt patiellls. (12-13)
Number ofunits. medium (range in parcnthescs)
Components
RI3C
FFP
PC
0)0.
lntraoperalivc
12(1-202)
12(0-189)
15(0-70)
8(0-119)
Postoperative
4(0-75)
14(0-123)
15(D-420)
1(0-180)
Total
19(3-211 )
24(0-20t)
25(D-449)
8(0-290)
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sell'cicci or proceeded with that in mind .For many_ the
period before transplantcHion is equally critical. since
blood componcnllhcrapy must be managed to minimize
alloimlllunizatioll. which may later bring about rejection
of the transplant and fillall) the marrow to be infused
Illust be selected or proceeded to avoid imlllunological
complications. This means removal of T lymphocytes
from the I1lClITO\\ before its infusion and at times.
extensive treatment of the recipient to remove or
neutralize ami A or anti B before tansplan!ation aran A
or B incompatible marrow.
lIccessful bone marrow transplant demands a
complete. dedicated. and well-trained slat[. Institutions
\\"ithoUI such facilities cannot expect to establish
sllccessful programmes.
Prctran.splant lllan:lgclllcllt
PresentI) marro\\ transplantation is done mostly for
patients \\ith aplastic anemia or acute leukemia, although
the number of experimental or quasi-experimental
transplClnts done for other diseases continues to rise
HLA compatibility is an important consideration. Hence
the first requirement for Cl potential marrow transplant
candidate is complete and accurate HLA typing. This
should be done early in the disease and ifal all possible
before transfusion therapy.
Homologous bone ll1"lrroW transplant
Transfusions before the homologous bone marrow
transplant are known to be detrimental since they
compromise the succcss of engraftment. particularly in
patients with aplastic anemia or leukemia, transfusion are
olkn necessary. Family mcmbers in pm1icular should be
avoided as blood donors prior to transplant since one of
them ma) be lIsed as bone marrow donor. This is most
important to patients with hypoplastic anemia and is of
less importance to patients with leukemia where graft
rejection is infrequent following bone marrow transplant
(16). The recipient must receive transfusion support until
engraftment occurs and blood cell production becomes
adequate. RBC's are usually given to maintain the
hemoglobin (Hb.) at 9-10 gmldl. This usually requires
6-20 units in 10 weeks ofpost transplant period. All blood
components (except buffy coats from the donor) must be
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irradiated (1500-5000 rad) to prevent gran verses host
disease (GYHD) and be ami CMY-negativc (CMY -vel if
the recipient and donor are CMV-\e. Platelet support rna)
also be needed for bone marrowtransplant recipients. liLA
identical or haploidentical ramily members are the ideal
donors for the preparation ofaphcrcsis platelets. but this is
not always possible and random donor p!atelels arc alien
used. These platelet transfusion 1113) be continued c\el)
2-4 days to maintain the platelet COLIllt in the recipient above
10-20 X \0 II. Ifthe patient becomes refractory to platelet
transfusion. therapy with HLA-matched platelets becomes
more important but is not always beneficial. Some cl:ntcrs
givc granulocyte transfusions prophylactically. \\ hich Illost
centers today give onl~ when antibiOlic resistant hacterial
infection develops. Since al1lll~A-identical donor is lIsuall)
required for bone marrow transplant. this donor (usuall) a
sibling) may not have thc same ABO andlor Rh-D type as
the patient. ABOand Rh-D identity orcompatibility between
the donor and Ihe recipient are nOi required for tbe success
ofbonc marrow transplant. but incompatibilities Illay pose
special problems for transfusion services.
Major ABO incompatibilil)'
Ifthe donor is group A and recipient is groupa (ABO
incompatibilities) then Ihe group A red cells oflhe donor in
aspirated marrow would be rapidly hemolysed in the
recipient due to recipient anti A. TIlis problcm can bc solved
by processing the aspirated marro\v to delete contamill<llcd
red cells (17). Fortunately stem cells do not express A and
B antigens. The group 0 recipient transplanted with group
A marrow may continuc to produce anti A and anti B for
3-4 months or in rare cases for 10-20 months post
transplant. The grafted marrow will begin to produce a
newpopulation ofblood cells. Group A red cells will appear
in the circulation \vhen thc recipient anti A disappears.
Hemolysis ofthe newly produced group A red cells may
be nOled aboUl2 months post transplant. This may last for
approximately 3 weeks and may result ill temporary drop
in patient's Hb. lflransfusions are necessary, washed group
a RBC's can be given, these componenls should be
CMV-ve ifthe patients has been determined as CMY-ve.
In addition all blood components transferred 10 BMT
recipients should be irradiated to prevent gran verses host
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disease. circulating donor WBCs are usually found about
C'I, \\eeks post BMT and platelets follow about 4 weeks
post BMT.
Minor side ABO ineompatability
When marrow from a groupa donor is transfused into
a non-group 0 recipient (A. B. AB), the plasma should
al\'a) s be rcmo\'cd in order to reduce incompatible
alloantibodies given to the recipient. However. in almost
10-15';0 of such BMT's. there is rather abrupt onset of
immune hemol)sis. \\hich begins about 7-8 days post
transplant and may last for :2 weeks. The direct AGT is
positi\'c. anti 1\ 01' anti 8 can be recovered in elutes aod the
hemolysis may result in hemoglobinemia and
hcmoglobinurea. An additional 30%ofsuch BMT recipicl1l
ma: dC\'t:lop a positiYC AGT but does not manifest gross
hcmol)sis. This phenomenon is due 10 '·passenger 8
lymphocytes" in the bone marrow that is producing
alloantibodies. This hemolysis is transient but may persist
for up 10 2 \\eeks and may rcquire transfusion. Irradiated
group 0 \\ashcd cells, CMV-ve ifthe recipient is CMV-ve,
would be the componcnt ofchoice.
This same phenomenon may develop following solid
organ transplants of kidney. liver, lungs. pancreas and
spleen. Typically there is an abrupt onset during the first 2-
3 wceks post transplant. Although usually transient, the
hemolysis may continue for up to six months.
Chcmcrism
[nspitc of intensive pretransplant chemotherapy and
irradiation. some ofthe host hcmopoietic cells may survive
and subsequently coexist with the transplanted donor cells.
This results. what has been turned mixed hemopoietic
chimerism and thus the recipient may have a duel cell
population. This phenomenon does not mean that the
recipient will necessarily have a recurrence ofthe hemolytic
malignancy.
Discussion
Although the organ or tissue transplants have become a
rOlltine in many good centers around the globe, the
transfusion support will continue to play an important role.
The story oforgan transplant and transfusion services has
had many twists and tums. For example the purpose of
"'idney transplantation has moved from avoidance to white
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cell depletion. to deliberate transfusion, to current vicw of
avoidance again.
In lung transplantation, the use of single lung
replacement or sequential bilateral replacement, improves
the outcome and reduces the need for cardiopulmonary
bypass and transfusion in comparison to traditional heart-
lung replacement (18).
Transfusion support in intestinal transplantation in one
ccnter used II units ofred cells in its first few cases (19)
where as some centers give cadaver donor blood to intestinal
transplant recipients (20). This concept ofcreating donor
l11icrochimcrisms via blood or bone marrow, to induce
tolerance is also under investigation in liver, kidney and
heart transplantation (21).
Transplant patients have also been benefitted from
experiences gained over the years. Improved perfusion
solutions like diasparine crosslinked hemoblobulin (DCL-
Hb.), is an altemativeto conventional crystalloid orcolloid
intravenous solutions and its major application is to treat
surgical and trauma patients to supplement or to eliminate
the need for blood transfusions and to improve the tissue
perfusion (22).
Greater surgical experience with procedures also lead
poorly functional organs and fewer re-operations for
bleeding in the immediate post-transplant period. Better
hemostasis of large bleeding surfaces can be obtained by
the use ofthe organ laser. The drug aprotinin. which is a
6S00-Kda-serine protease inhibitor, derived from bovine
pancreas has number ofsubstrates. In decreasing potency
it inhibits plasmin, plasma kallikerein, APC(activated protein
complex - factor XIa, factor Va and tissue factor complex)
two chain urokinase, factor Xa and thrombin. Aprotonin
significantly prolongs activated thromboplastin time
(APPT) but not prothrombin time (PT), most probably as
a result of its effect on IXa and plasma kallikrein.
Since kallikrein is not associated with bleeding and
factor XI deficiency is considered a mild bleedingdisorder,
these combined data suggest that aprotinin is a better
inhibitor of fibrinolytic pathways than of thrombin
fonnation (23-26).
Aprotinin is licensed in United States for reducing blood
use in cardiac surgery. However, risks of thrombosis and
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anaphylaclic reactions have been reported. Some of
thrombocytopenia in liver failure may be due to
thrombopoielic deficiency and thus thrombopoietic
therap) rna) become useful when a liver transplant is
imminent ('27).
To conclude, in future blood transfusion services will
be called all for support of artificial organ transplant or
XCllctransplant frol11 animals. This almost 360-degreeevo-
lution, resulling from added knowledge and the develop-
ment ofnew drugs. illustrates both past challenge and the
Oexibility required for the future. The lesson we learned so
far will serve as critical building blocks for our transplan-
tation colleagues' new age ofadvance.
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